Activities of Emmanuel MAUREL related to 2020/2071(INI)
Shadow opinions (2)
OPINION on shortage of medicines – how to address an emerging problem
Opinion on "Shortage of medicines: how to address an emerging problem"
Amendments (4)
Amendment 12 #
Draft opinion
Paragraph 2
Paragraph 2
2. Recognises that the EU depends on a narrow set of countries for a large proportion of its imports of active pharmaceutical ingredients and chemical raw materials; stresses that the lack of strategic autonomy and the high dependence of the European Union in a key sector such as health and the production of medicines is the concrete expression of the exacerbated free trade as promoted by the European Commission for decades; stresses that this over- reliance can pose a risk when limitations in production capacity, excess demand or protectionist measures threaten the proper functioning of global supply chains and potentially undermine the availability of medicines in the EU; calls on the Commission to present a long-term strategy focused on ensuring the EU’s open strategic autonomy in health;
Amendment 13 #
Draft opinion
Paragraph 2
Paragraph 2
2. Recognises that the EU depends on a narrow set of countries for a large proportion of its imports of active pharmaceutical ingredients and chemical raw materials; stresses that this over- reliance can pose a risk when limitations in production capacity, excess demand or protectionist measures threaten the proper functioning of global supply chains and potentially undermine the availability of medicines in the EU; calls on the Commission to present a long-term strategy focused on ensuring the EU’s open strategic autonomy in health; asks for a prior European or Member State allowance to any project of outsourcing health-related or pharmaceutical productions outside the EU;
Amendment 28 #
Draft opinion
Paragraph 3
Paragraph 3
3. Emphasises that the EU is a leading global exporter of pharmaceutical products; notes that the protection and enforcement of IP rights in free trade agreements (FTAs) and at the WTO is crucial to the development of new medicines and treatments; underlines that the flexibilities provided in the TRIPS agreement can be used to address potential supply shortages in exceptional circumstances; asks for an European Health Exception notified to the WTO and included in all trade agreements, past and future, keeping a zero tariff on pharmaceutical products but allowing parties to provide state aid to their domestic health-related and pharmaceutical sector; asks for a regulation on the disqualification of any future dispute raised by our FTA partners on the health issue;
Amendment 54 #
Draft opinion
Paragraph 6
Paragraph 6
6. Underlines that a complete repatriation of medical supply chains is not possible in a global economy; urges the Commission and theasks for an European directive allowing Member States to wforkce, with the EU’s partners, the WHO and WTO, on establishing an international framework that can prevent the breakdown of supply chains and limit resin 5 years, quotas of domestic production of various drugs (for instance basic drugs like acetaminophen or antibiotics, also substances needed in critical care units, like opiates or anesthetics), raw materials needed fort toheir proteductionist measures during health crises, medical devices and medical clothing.